Jefferies analyst Akash Tewari maintained a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report) today and set a price target of $170.00.
Akash Tewari has given his Buy rating due to a combination of factors including Jazz Pharmaceuticals’ strong financial performance and promising future outlook. The company reported higher-than-expected revenues and earnings per share, which exceeded consensus estimates, indicating robust operational efficiency. Furthermore, management’s guidance for fiscal year 2025 suggests achievable growth targets, with revenue projections aligning well with historical trends.
Additionally, Jazz Pharmaceuticals is strategically prioritizing its research and development pipeline, which is expected to optimize operational expenses. The company is also focusing on potential mergers and acquisitions, as well as debt reduction and share repurchases, which could enhance shareholder value. The analyst also notes the potential of Jazz’s product portfolio, particularly in the oxybate business and Zani in gastrointestinal cancers, which could significantly contribute to future revenue growth.
Tewari covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Pfizer, and Bristol-Myers Squibb. According to TipRanks, Tewari has an average return of 10.2% and a 51.31% success rate on recommended stocks.
In another report released today, Stifel Nicolaus also maintained a Buy rating on the stock with a $230.00 price target.